Apixaban
From Wikipedia, the free encyclopedia
 |
|
|
Apixaban
|
|
| Systematic (IUPAC) name | |
| 1-(4-methoxyphenyl)-7-oxo-6-[4- (2-oxopiperidin-1-yl)phenyl]-4,5- dihydropyrazolo[5,4-c]pyridine- 3-carboxamide |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C25H25N5O4 |
| Mol. mass | 459.497 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | oral |
Apixaban (manufacturer's designation BMS-562247-01) is a compound being investigated as an anticoagulant. It acts by inhibiting coagulation factor Xa. It is presently undergoing phase III trials in the prevention of venous thromboembolism, together with a number of related competing compounds, such as rivaroxaban.[1] It is being marketed in a joint venture by Pfizer and Bristol-Myers Squibb.[2]
A 2007 trial showed that apixaban was equivalent to enoxaparin/open-label heparin in preventing thrombosis is patients who had undergone a knee replacement.[3]
[edit] References
- ^ Turpie AG (2007). "Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases". Arterioscler. Thromb. Vasc. Biol. 27 (6): 1238-47. doi:. PMID 17379841.
- ^ Bristol-Myers Squibb News Release 26 April 2007. Retrieved on 2007-09-15.
- ^ Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D (2007). "The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement". J. Thromb. Haemost. 5 (12): 2368–75. doi:. PMID 17868430.
|
||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
